Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
11.11
+1.17 (11.77%)
Jul 24, 2025, 4:00 PM - Market closed

Company Description

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally.

The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd.
Sol-Gel Technologies logo
CountryIsrael
Founded1997
IPO DateJan 23, 2018
IndustryBiotechnology
SectorHealthcare
Employees34
CEOMoshe Arkin

Contact Details

Address:
7 Golda Meir Street, Weizmann Science Park
Ness Ziona, 7403650
Israel
Phone972 8 931 3433
Websitesol-gel.com

Stock Details

Ticker SymbolSLGL
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001684693
CUSIP NumberM8694L137
ISIN NumberIL0011417206
SIC Code2834

Key Executives

NamePosition
Moshe ArkinChief Executive Officer and Executive Chairman
Tamar Fishman JutkowitzVice President and General Counsel
Eyal Ben-OrChief Financial Officer
Dr. Itzik YosefChief Operating Officer
Michael GlezinChief Business Officer

Latest SEC Filings

DateTypeTitle
Jun 12, 2025SCHEDULE 13D/AFiling
May 23, 2025424B3Prospectus
May 23, 20256-KReport of foreign issuer
May 22, 20256-KReport of foreign issuer
May 8, 2025EFFECTNotice of Effectiveness
May 8, 2025424B3Prospectus
May 8, 20256-K/AFiling
May 5, 20256-KReport of foreign issuer
May 2, 2025UPLOADFiling
Apr 30, 2025EFFECTNotice of Effectiveness